Patents Represented by Attorney, Agent or Law Firm Elias J. Lambiris, Esq.
  • Patent number: 5688663
    Abstract: The present invention relates to a gene encoding an ascomycete or deuteromycete carboxypeptidase Y gene, and host cells modified so as to produce reduced amounts of carboxypeptidase.
    Type: Grant
    Filed: February 28, 1996
    Date of Patent: November 18, 1997
    Assignee: Novo Nordisk Biotech, Inc.
    Inventors: Debbie Sue Yaver, Sheryl Ann Thompson
  • Patent number: 5688757
    Abstract: Certain sugar derivatives have bleach-activating effect both on "hydrophilic" stains (e.g. tea or red wine) and on "hydrophobic" stains (e.g. grass or tomato sauce). The compounds in question are derivatives of pentoses or hexoses, having a long-chain acyl group and one or more short-chain acyl or aroyl groups attached through ester bonds. Optionally, a short-chain alkyl group is attached through a glycosidic bond. These compounds are non-toxic and biodegradable, and can conveniently be prepared by methods known in the art.
    Type: Grant
    Filed: January 7, 1994
    Date of Patent: November 18, 1997
    Assignees: Novo Nordisk A/S The Procter & Gamble Co., Novo Alle
    Inventors: Ture Damhus, Ole Kirk, Frederick Edward Hardy
  • Patent number: 5688788
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: November 18, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
  • Patent number: 5686593
    Abstract: The present invention relates to cellulose- or hemicellulose-degrading enzymes which is derivable from a fungus other than Trichoderma or Phanerochaete, and which comprises a carbohydrate binding domain homologous to a terminal A region of Trichoderma reesei cellulases, which carbohydrate binding domain comprises the following amino acid sequence. ##STR1## or a subsequence thereof capable of effecting binding of the enzyme to an insoluble cellulosic or hemicellulosic substrate.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 11, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Helle Fabricius Woldike, Fred Hagen, Carsten Mailand Hjort, Sven Hastrup
  • Patent number: 5686124
    Abstract: The method for restructuration of raw meat for production of restructured raw meat by addition to the meat of transglutaminase comprises the further addition of phosphate (optional) and sodium chloride, with a subsequent temperature treatment. Hereby the cohesion and hardness of the restructured raw meat is improved, and it can be sold as a refrigerated meat product.
    Type: Grant
    Filed: March 8, 1996
    Date of Patent: November 11, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Anders Juel M.o slashed.ller, Ghita Studsgaard Nielsen, Bent Riber Petersen
  • Patent number: 5683989
    Abstract: The present invention relates to compounds of formula I ##STR1## wherein X is amino, C.sub.1-6 -alkylamino, di-C.sub.1-6 -alkylamino;R.sup.1 is H, straight or branched C.sub.1-6 -alkyl or trifluoromethyl; R.sup.4 is H or straight or branched C.sub.1-6 -alkyl; or R.sup.1 and R.sup.4 together form a cyclobutyl, cyclopentyl or cyclohexyl ring;Y is O, S, SO.sub.2, N--H or N-alkyl;R.sup.5 is selected from optionally substituted heterocycles;R.sup.6 is hydrogen, benzoyl or C.sub.1-6 -alkanoyl andR.sup.7 is hydrogen, benzoyl or C.sub.1-6 -alkanoyl; ora pharmaceutically acceptable salt thereof.The compounds have been found useful for treating central nervous system and cardiovascular ailments.
    Type: Grant
    Filed: July 20, 1995
    Date of Patent: November 4, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Lars Jacob Stray Knutsen, Malcolm Sheardown, Anker Jon Hansen
  • Patent number: 5680858
    Abstract: A method for in vivo determination of the concentration in a body fluid of metabolically significant substance comprises storing of a needle with a sensor in a liquid-filled ampoule, brief insertion of the needle into a patient, recording of the output signal from the sensor, withdrawal of the needle, and calculation of the concentration looked for on the basis of the recorded signals. The method is preformed using an apparatus comprising a needle (5) with a sensor (6), an ampoule (1) containing a solution (2) and closed by two membranes (3, 4). The needle (5) is stored with its sensor (6) in the solution. The apparatus further comprises a mechanical unit for driving the needle (5) to protrude from the ampoule for a set moment, and an electronic unit storing the output signal from the sensor (6) and performing calculations on the basis of the stored signal values.
    Type: Grant
    Filed: July 6, 1995
    Date of Patent: October 28, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Henrik-Egesborg Hansen, Henrik Ege, Thomas Munk Plum
  • Patent number: 5681725
    Abstract: Process for producing an extracellular heme protein in increased yields, the process comprising culturing an apoprotein producing microorganism in a fermentation medium containing heme or a heme-containing material under conditions permitting the production of active, recombined heme protein, and recovering the resulting heme protein from the culture medium.
    Type: Grant
    Filed: August 9, 1994
    Date of Patent: October 28, 1997
    Assignee: Novo Nordisk A/S
    Inventor: Ejner Bech Jensen
  • Patent number: 5679686
    Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 21, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Franklin Porter Bymaster, Harlan E. Shannon, Per Sauerberg, Preben H. Olesen, John Stanley Ward, Charles H. Mitch
  • Patent number: 5677313
    Abstract: The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 14, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Franklin Porter Bymaster, Harlan E. Shannon, Per Sauerberg, Preben H. Olesen, John Stanley Ward, Charles H. Mitch
  • Patent number: 5674833
    Abstract: A detergent composition and additive comprising a protease and a reversible protease inhibitor of the peptide or protein type, wherein the ratio of the dissociation constant to the protease concentration in the range from 0.006 to 6. When the protease is subtilisin, the protease inhibitor is preferably a modified subtilisin inhibitor of Family VI.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: October 7, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Jan M.o slashed.ller Mikkelsen, Allan Svendsen, B.o slashed.rge Diderichsen, Ib Groth Clausen
  • Patent number: 5672588
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is hydrogen, amino, halogen, hydroxy, lower alkoxy or lower alkyl andR.sup.1 is ##STR2## wherein Y is methylene or a valence bond, R.sup.2 and R.sup.5 is H or lower, straight or branched alkyl,R.sup.3 is H or lower alkyl, orR.sup.2 and R.sup.3 can together form a cyclobutyl, cyclopentyl, cyclohexyl or phenyl ring,Z is oxygen, methylene, sulphur, sulphonyl or a valence bond,R.sup.4 is H, lower alkyl, aralkyl, a mono or bicyclic aromatic system optionally substituted with various groups.The compounds have been found useful for treating central nervous system ailments.
    Type: Grant
    Filed: August 28, 1995
    Date of Patent: September 30, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Lars Jacob Stray Knutsen, Jesper Lau
  • Patent number: 5668129
    Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: March 27, 1996
    Date of Patent: September 16, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
  • Patent number: 5665587
    Abstract: The present invention relates to modified subtilisins comprising a mutation in an amino acid sequence of a subtilisin at a position selected from the group consisting of 1, 2, 3, 4, 6, 9, 10, 12, 14, 15, 17, 18, 19, 20, 21, 22, 24, 25, 27, 36, 37, 38, 40, 41, 43, 44, 45, 46, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 75, 76, 77, 78, 79, 87, 89, 91, 94, 97, 98, 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 112, 113, 115, 116, 117, 118, 120, 126, 128, 129, 130, 131, 133, 134, 136, 137, 140, 141, 143, 144, 145, 146, 155, 156, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 170, 171, 172, 173, 181, 182, 183, 184, 185, 186, 188, 189, 191, 192, 194, 195, 197, 204, 206, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 247, 248, 249, 251, 252, 253, 254, 255, 256, 257, 259, 260, 261, 262, 263, 265, 269, 271, 272 and 275. The present invention also relates to detergent compositions comprising a modified subtilisin of the present invention.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 9, 1997
    Assignees: Novo Nordisk A/S, Unilever PLC
    Inventors: Dorrit Aaslyng, Sven Branner, Sven Hastrup, Leif N.o slashed.rskov-Lauritsen, Ole Hvilsted Olsen, Merete Simonsen, Eric Casteleijn, Maarten Robert Egmond, Johan Haverkamp, John David Marugg, Arnoldus Theodorus Anthonius Mooren
  • Patent number: 5658932
    Abstract: The present invention relates to therapeutically active azacyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: August 19, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Per Sauerberg, Preben H. Olesen, Charles H. Mitch
  • Patent number: 5650315
    Abstract: An alkaline serine protease is disclosed which is obtainable from Bacillus sp. JA16-38A, NCIMB No. 40263 and which (a) has a pH optimum in the range of 9-11 determined at 25.degree. C.; (b) has a temperature optimum in the range of 40.degree.-50.degree. C. determined at pH 9.5; (c) is active in the presence of ethylene-diamine tetraacetate; and (d) has a mass of about 28 kD determined by SDS-PAGE. Detergent additives and detergent compositions comprising said protease and methods for producing said protease are also disclosed.
    Type: Grant
    Filed: August 18, 1993
    Date of Patent: July 22, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Helle Outtrup, Claus Dambmann, Dorrit A. Aaslyng
  • Patent number: 5648263
    Abstract: The present invention relates to methods of reducing the rate at which a cotton-containing fabric becomes harsh or of reducing the harshness of a cotton-containing fabric, comprising treating the cotton-containing fabric with a cellulase preparation obtained from a fungus, wherein the cellulase preparation comprises a substantially homogeneous endoglucanase component which: (a) has a pH optimum of about 7.5-10.0; (b) exhibits a CMC endoase activity of at least about 10 CMC-endoase units per mg of total protein; (c) exhibits a CAVU activity of at least about 50% at a pH of 7.0-12.0; and (d) has essentially no cellobiohydrolase activity; wherein at least about 50% by weight of the total cellulase content of the cellulase preparation is the endoglucanase component.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: July 15, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Martin Schulein, Kirsten B.o slashed.egh Levring
  • Patent number: 5646146
    Abstract: The present invention relates to 9H-indeno[1,2-b]pyrazin-3(4H)-ones and 9H-indeno[1,2-b]pyrazine-2,3(1H,4H)-diones or tautomeric forms thereof which are useful in treating neurological and psychiatric diseases based on the antagonism of the glycine binding site on the NMDA receptor complex.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: July 8, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Peter Faarup, Palle Jakobsen, Anker Steen J.o slashed.rgensen, Henrik Klitgaard
  • Patent number: 5646025
    Abstract: The present invention relates to a nucleic acid construct containing a nucleic acid sequence encoding a Scytalidium catalase enzyme, as well as vectors and host cells comprising the construct.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: July 8, 1997
    Assignee: Novo Nordisk A/S
    Inventor: Donna Moyer
  • Patent number: 5641791
    Abstract: The present invention relates to therapeutically active azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: June 24, 1997
    Assignee: Novo Nordisk A.S
    Inventors: Per Sauerberg, Preben H. Olesen